查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474877

抗体药物复合体市场规模、份额、趋势分析报告：按应用、按技术、按产品、按目标、按地区、细分市场预测，2024-2030

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

抗体药物偶联物市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球抗体药物偶联物市场规模将达到240.1亿美元，预测期内复合年增长率为9.2%。

强大的研发线产品和主要企业的策略倡议的出现预计将在预测期内推动市场成长。

ADC Therapeutics、Seagen.Inc.、武田药品工业株式会社、F. Hoffmann-La Roche Ltd.、阿斯特捷利康、第一三共等公司正在合作开发和商业化该产品。例如，2022年2月，Mersana Therapeutics与强生公司子公司杨森製药公司合作，研发新型ADC来治疗各种癌症。根据协议，杨森製药公司将向 Mersana Therapeutics 支付 4,000 万美元的预付款，并可能为新 ADC 开发的里程碑支付超过 10 亿美元。

製药公司对新型抗体药物偶联物开发的广泛研究和不断增加的资金筹措预计将推动市场成长。例如，2021 年 4 月，两家新新兴企业Adcendo 和 Adcentrx 筹集了约 1.12 亿美元的资金，用于开发具有癌症治疗新方法的 ADC。 Adcendo 已筹集 5,100 万美元用于开发一种针对内吞受体（充当药物传输载体）的新型 ADC。 Adcentrx 已为其 ADC 研究计画筹集了 5,000 万美元。

此外，2022 年 3 月，ImmunoGen, Inc. 宣布已向美国FDA 提交了 mirvetuximab soravtansine 单药治疗卵巢癌患者的生技药品许可申请 (BLA)。该製剂由 α 连接抗体、可裂解接头和作为有效负载杀死目标癌细胞的美登木素生物碱 DM4 组成。

与单株抗体疗法和化疗等替代传统疗法相比，ADC 的治疗高成本，因此严格的 ADC 报销政策可能会抑制市场成长。这种治疗的高昂费用预计会阻碍报销。例如，2020年2月，爱尔兰国家药物经济学中心对罗氏Kadcyla （曲妥珠单抗emtansine）给予报销负面审查，理由是其缺乏成本效益。

老年人口的增加和多发性骨髓瘤 (MM) 等疾病盛行率的增加预计将推动预测期内对 ADC 的需求并推动市场成长。多发性骨髓瘤 (MM) 是一种人口老化疾病，2021 年诊断出近 30,000 例新发 MM 病例。被诊断为多发性骨髓瘤的患者的中位年龄为 70 岁。因此，采用新型 ADC 进行多发性骨髓瘤治疗预计将促进市场成长。例如，2020年8月，FDA核准GlaxoSmithKline Plc的BLENREP作为单一疗法治疗復发或难治性多发性骨髓瘤。 Brenrep 是第一个核准用于治疗多发性骨髓瘤的抗 BCMA 疗法。

抗体药物偶联物市场报告亮点

  • 由于乳癌的高盛行率以及多种用于乳癌治疗的 ADC 产品的可用性，乳癌在 2023 年以 47.76% 的最大销售份额占据市场主导地位。
  • 由于商业ADC产品中越来越多地采用可裂解连接器技术，以及使用可裂解连接器相对于其他连接器技术的优势，可裂解连接器细分市场将在2023年增长72.43%，占收益占有率。
  • 从连接器技术类型来看，市场上有许多高效的连接器用于将有效负载传递到目标位点，例如SMCC、SPP、MCC、胜肽、CL2A、MC（马来酰亚胺己酰基）等。
  • 由于辉瑞公司（Pfizer, Inc.）、吉利德生命科学公司（Gilead Life Sciences, Inc.）和希根公司（Seagen, Inc.）等主要製药公司的存在，以及开发新ADC 的策略努力，2023 年北美将收益占有率52.54% 的收入市场份额被垄断了。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
  • 市场动态
    • 存在强大的产品平臺
    • 人口老化加剧
    • 癌症发生率和盛行率增加
  • 市场限制因素分析
    • ADC 的高製造成本与下游加工挑战
    • ADC 分析挑战
    • 严格的 ADC 报销政策
  • 营商环境分析
    • 依因素（政治/法律、经济/技术）进行 SWOT 分析
    • 波特五力分析
    • COVID-19 影响分析
  • ADC开发平台定性分析
    • Creative Biolabs
    • Mersana Therapeutics
    • Heidelberg Pharma
    • Synaffix BV
    • NBE Therapeutics
    • VERAXA
    • Tubulis Gmbh
    • Byondis Platform
    • Immunogen, Inc.
    • RemeGen
    • Wuxi Biologics
    • Merck & Co., Inc.
    • Ambrx

第四章抗体药物偶联物市场：按应用細項分析，2018-2030（百万美元）

  • 抗体药物偶联物市场：应用变化分析
  • 血癌
  • 乳癌
  • 尿路上皮癌/膀胱癌
  • 其他的

第五章抗体药物偶联物市场：按产品細項分析，2018-2030（百万美元）

  • 抗体药物偶联物市场：产品波动分析
  • 门头
  • 恩赫图
  • ADCETRIS
  • 帕多切夫
  • 波利维
  • 其他的

第六章抗体药物偶联物市场：按目标細項分析，2018-2030（百万美元）

  • 抗体药物偶联物市场：标靶变异分析
  • HER2
  • CD22
  • CD30
  • 其他的

第 7 章抗体药物偶联物市场：按技术細項分析，2018-2030 年（百万美元）

  • 抗体药物偶联物市场：技术变化分析
  • 按类型
  • 连接器技术
  • 有效载荷技术

第八章抗体药物偶联物市场：区域分析，2018-2030（百万美元）

  • 2022年及2030年抗体药物偶联物市场占有率（按地区）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2023年主要企业市场占有率分析
  • 公司简介
    • Takeda Pharmaceutical Company Limited
    • F.Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Astrazeneca
    • Gilead Sciences, Inc.
    • Astellas Pharma Inc.
    • Seagen, Inc.
    • Daiichi Sankyo Company, Limited
    • Glaxosmithkline Plc.
    • Adc Therapeutics Sa
    • Synaffix Bv

第10章 Kol建议/结论

Product Code: GVR-2-68038-741-4

Antibody Drug Conjugates Market Growth & Trends:

The global antibody drug conjugates market size is expected to reach USD 24.01 billion by 2030, registering a CAGR of 9.2% during the forecast period, according to a new report by Grand View Research, Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U.S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche's Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody Drug Conjugates Market Report Highlights:

  • Breast cancer dominated the market for the largest revenue share of 47.76% in 2023, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
  • Cleavable linker segment accounted for largest revenue share of 72.43% in 2023 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
  • Based on linker Technology Type, others segment dominated the market due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.
  • North America dominated the market in terms of revenue share of 52.54% in 2023 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Technology Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR' s Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology And Application Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Presence Of Strong Product Pipeline
    • 3.4.2. Growing Geriatric Population Base
    • 3.4.3. Increasing Incidence And Prevalence Of Cancer
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Manufacturing Cost And Downstream Processing Challenges For ADCs
    • 3.5.2. Analytical Challenges For ADCs
    • 3.5.3. Stringent Reimbursement Policies For ADCs
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis
  • 3.7. Qualitative Analysis For ADC Development Platforms
    • 3.7.1. Creative Biolabs
    • 3.7.2. Mersana Therapeutics
    • 3.7.3. Heidelberg Pharma
    • 3.7.4. Synaffix BV
    • 3.7.5. NBE Therapeutics
    • 3.7.6. VERAXA
    • 3.7.7. Tubulis Gmbh
    • 3.7.8. Byondis Platform
    • 3.7.9. Immunogen, Inc.
    • 3.7.10. RemeGen
    • 3.7.11. Wuxi Biologics
    • 3.7.12. Merck & Co., Inc.
    • 3.7.13. Ambrx

Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 - 2030 (USD Million)

  • 4.1. Antibody Drug Conjugates Market: Application Movement Analysis
  • 4.2. Blood Cancer
    • 4.2.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.2. Leukemia
      • 4.2.2.1. Leukemia Market, 2018 - 2030 (USD Million)
    • 4.2.3. Multiple Myeloma
      • 4.2.3.1. Multiple Myeloma Market, 2018 - 2030 (USD Million)
    • 4.2.4. Lymphoma
      • 4.2.4.1. Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.3. Breast Cancer
  • 4.4. Urothelial/Bladder Cancer
    • 4.4.1. Urothelial/Bladder Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Product, 2018 - 2030 (USD Million)

  • 5.1. Antibody Drug Conjugates Market: Product Movement Analysis
  • 5.2. Kadcyla
    • 5.2.1. Kadcyla Market, 2018 - 2030 (USD Million)
  • 5.3. Enhertu
    • 5.3.1. Enhertu Market, 2018 - 2030 (USD Million)
  • 5.4. Adcetris
    • 5.4.1. Adcetris Market, 2018 - 2030 (USD Million)
  • 5.5. Padcev
    • 5.5.1. Padcev Market, 2018 - 2030 (USD Million)
  • 5.6. Polivy
    • 5.6.1. Polivy Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Segment Analysis By Target, 2018 - 2030 (USD Million)

  • 6.1. Antibody Drug Conjugates Market: Target Movement Analysis
  • 6.2. HER2
    • 6.2.1. HER2 Market, 2018 - 2030 (USD Million)
  • 6.3. CD22
    • 6.3.1. CD22 Market, 2018 - 2030 (USD Million)
  • 6.4. CD30
    • 6.4.1. CD30 Market, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 - 2030 (USD Million)

  • 7.1. Antibody Drug Conjugates Market: Technology Movement Analysis
  • 7.2. By Type
    • 7.2.1. Cleavable Linker
      • 7.2.1.1. Cleavable Linker Market, 2018 - 2030 (USD Million)
    • 7.2.2. Non-Cleavable Linker
      • 7.2.2.1. Non-Cleavable Linker Market, 2018 - 2030 (USD Million)
    • 7.2.3. Linkerless
      • 7.2.3.1. Linkerless Market, 2018 - 2030 (USD Million)
  • 7.3. By Linker Technology
    • 7.3.1. Vc (Valine-Citrulline)
      • 7.3.1.1. Vc Market, 2018 - 2030 (USD Million)
    • 7.3.2. Sulfo-SPDB
      • 7.3.2.1. Sulfo-SPDB Market, 2018 - 2030 (USD Million)
    • 7.3.3. VA (Valine Alanine)
      • 7.3.3.1. VA (Valine Alanine) Market, 2018 - 2030 (USD Million)
    • 7.3.4. Hydrazone
      • 7.3.4.1. Hydrazone Market, 2018 - 2030 (USD Million)
    • 7.3.5. Others
      • 7.3.5.1. Others Market, 2018 - 2030 (USD Million)
  • 7.4. By Payload Technology
    • 7.4.1. MMAE
      • 7.4.1.1. MMAE Market, 2018 - 2030 (USD Million)
    • 7.4.2. MMAF
      • 7.4.2.1. MMAF Market, 2018 - 2030 (USD Million)
    • 7.4.3. Dm4
      • 7.4.3.1. Dm4 Market, 2018 - 2030 (USD Million)
    • 7.4.4. Camptothecin
      • 7.4.4.1. Camptothecin Market, 2018 - 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Regional Analysis, 2018 - 2030 (USD Million)

  • 8.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. Swot Analysis
    • 8.2.2. North America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Canada Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Swot Analysis
    • 8.3.2. Europe Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.4. UK
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. UK Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. France Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Italy Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Spain Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Reimbursement Scenario
      • 8.3.10.6. Norway Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Swot Analysis
    • 8.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. Japan Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. China Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. India Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Australia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Reimbursement Scenario
      • 8.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Swot Analysis
    • 8.5.2. Latin America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Reimbursement Scenario
      • 8.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa (MEA)
    • 8.8.1. Swot Analysis
    • 8.8.2. MEA Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.3. South Africa
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Competitive Scenario
      • 8.8.3.4. Regulatory Framework
      • 8.8.3.5. Reimbursement Scenario
      • 8.8.3.6. South Africa Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.4. Saudi Arabia
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Competitive Scenario
      • 8.8.4.4. Regulatory Framework
      • 8.8.4.5. Reimbursement Scenario
      • 8.8.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.5. UAE
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Competitive Scenario
      • 8.8.5.4. Regulatory Framework
      • 8.8.5.5. Reimbursement Scenario
      • 8.8.5.6. UAE Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
    • 8.8.6. Kuwait
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Target Disease Prevalence
      • 8.8.6.3. Competitive Scenario
      • 8.8.6.4. Regulatory Framework
      • 8.8.6.5. Reimbursement Scenario
      • 8.8.6.6. Kuwait Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1 Company Categorization
  • 9.2 Strategy Mapping
    • 9.2.1 New Product Launch
    • 9.2.2 Partnerships
    • 9.2.3 Acquisition
    • 9.2.4 Collaboration
    • 9.2.5 Funding
  • 9.3 Key Company Market Share Analysis, 2023
  • 9.4 Company Profiles
    • 9.4.1 Takeda Pharmaceutical Company Limited
      • 9.4.1.1 Company Overview
      • 9.4.1.2 Financial Performance
      • 9.4.1.3 Product Benchmarking
      • 9.4.1.4 Strategic Initiatives
    • 9.4.2 F.Hoffmann-La Roche Ltd.
      • 9.4.2.1 Company Overview
      • 9.4.2.2 Financial Performance
      • 9.4.2.3 Product Benchmarking
      • 9.4.2.4 Strategic Initiatives
    • 9.4.3 Pfizer, Inc.
      • 9.4.3.1 Company Overview
      • 9.4.3.2 Financial Performance
      • 9.4.3.3 Product Benchmarking
      • 9.4.3.4 Strategic Initiatives
    • 9.4.4 Astrazeneca
      • 9.4.4.1 Company Overview
      • 9.4.4.2 Product Benchmarking
      • 9.4.4.3 Strategic Initiatives
    • 9.4.5 Gilead Sciences, Inc.
      • 9.4.5.1 Company Overview
      • 9.4.5.2 Financial Performance
      • 9.4.5.3 Product Benchmarking
      • 9.4.5.4 Strategic Initiatives
    • 9.4.6 Astellas Pharma Inc.
      • 9.4.6.1 Company Overview
      • 9.4.6.2 Financial Performance
      • 9.4.6.3 Product Benchmarking
      • 9.4.6.4 Strategic Initiatives
    • 9.4.7 Seagen, Inc.
      • 9.4.7.1 Company Overview
      • 9.4.7.2 Financial Performance
      • 9.4.7.3 Product Benchmarking
      • 9.4.7.4 Strategic Initiatives
    • 9.4.8 Daiichi Sankyo Company, Limited
      • 9.4.8.1 Company Overview
      • 9.4.8.2 Financial Performance
      • 9.4.8.3 Product Benchmarking
      • 9.4.8.4 Strategic Initiatives
    • 9.4.9 Glaxosmithkline Plc.
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.10 Adc Therapeutics Sa
      • 9.4.10.1 Company Overview
      • 9.4.10.2 Financial Performance
      • 9.4.10.3 Product Benchmarking
      • 9.4.10.4 Strategic Initiatives
    • 9.4.11 Synaffix Bv
      • 9.4.11.1 Company Overview
      • 9.4.11.2 Financial Performance
      • 9.4.11.3 Product Benchmarking
      • 9.4.11.4 Strategic Initiatives

Chapter 10. Kol Recommendations/ Conclusion

List of Tables

  • TABLE 1 List of abbreviation
  • TABLE 2 List of secondary sources
  • TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
  • TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 8 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 9 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 13 North America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 14 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 15 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 16 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 17 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 18 U.S. antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 19 U.S. antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 20 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 21 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 22 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 23 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Canada antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 25 Canada antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 26 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 27 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 28 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 29 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 30 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 31 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 32 Europe antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 33 Europe antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 34 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 35 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 36 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 37 UK antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 38 UK antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 39 UK antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 40 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 41 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 42 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 43 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Germany antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 45 Germany antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 46 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 47 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 48 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 49 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 50 France antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 51 France antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 52 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 53 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 54 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 55 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 56 Italy antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 57 Italy antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 58 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 59 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 60 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 61 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 62 Spain antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 63 Spain antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 64 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 65 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 66 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 67 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 68 Denmark antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 69 Denmark antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 70 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 71 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 72 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 73 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 74 Sweden antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 75 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 76 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 77 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 78 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 79 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 80 Norway antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 81 Norway antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 82 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 83 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 84 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 85 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 86 Asia Pacific antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 87 Asia Pacific antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 88 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 89 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 90 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 91 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 92 Japan antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 93 Japan antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 94 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 95 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 96 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 97 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 98 China antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 99 China antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 100 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 101 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 102 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 103 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 104 India antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 105 India antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 106 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 107 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 108 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 109 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 110 Australia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 111 Australia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 112 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 113 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 114 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 115 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 116 South Korea antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 117 South Korea antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 118 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 119 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 120 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 121 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 122 Thailand antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 123 Thailand antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 124 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 125 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 126 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 127 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 128 Latin America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 129 Latin America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 130 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 131 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 132 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 133 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 134 Brazil antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 135 Brazil antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 136 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 137 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 138 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 139 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 140 Mexico antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 141 Mexico antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 142 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 143 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 144 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 145 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 146 Argentina antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 147 Argentina antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 148 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 149 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 150 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 151 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 152 MEA antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 153 MEA antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 154 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 155 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 156 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 157 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 158 South Africa antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 159 South Africa antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 160 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 161 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 162 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 163 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 164 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 165 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 166 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 167 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 168 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 169 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 170 UAE antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 171 UAE antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 172 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 173 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 174 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 175 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 176 Kuwait antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 177 Kuwait antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
  • TABLE 178 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
  • TABLE 179 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
  • TABLE 180 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
  • TABLE 181 List of key distributors
  • TABLE 182 List of key emerging companies/technology disruptors/innovators

List of Figures

  • FIG. 1 Antibody-drug conjugates market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Antibody-drug conjugates market snapshot
  • FIG. 10 Antibody-drug conjugates market driver impact
  • FIG. 11 Global population by age group, 2016, 2022, & 2027
  • FIG. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
  • FIG. 13 Antibody-drug conjugates market restraint impact
  • FIG. 14 Penetration and growth prospect mapping
  • FIG. 15 SWOT analysis, by factor (political & legal economic and technological)
  • FIG. 16 Porter's five forces analysis
  • FIG. 17 Antibody-drug conjugates market: Application outlook and key takeaways
  • FIG. 18 Antibody-drug conjugates market: Application movement analysis
  • FIG. 19 Blood cancer market estimates and forecasts, 2018 - 2030
  • FIG. 20 Leukemia market estimates and forecasts, 2018 - 2030
  • FIG. 21 Multiple Myeloma market estimates and forecasts, 2018 - 2030
  • FIG. 22 Lymphoma market estimates and forecasts, 2018 - 2030
  • FIG. 23 Breast cancer market estimates and forecasts, 2018 - 2030
  • FIG. 24 Urothelial cancer market estimates and forecasts, 2018 - 2030
  • FIG. 25 Others market estimates and forecasts, 2018 - 2030
  • FIG. 26 Antibody-drug conjugates market: Product outlook and key takeaways
  • FIG. 27 Antibody-drug conjugates market: Product movement analysis
  • FIG. 28 Kadcyla market estimates and forecasts, 2018 - 2030
  • FIG. 29 Enhertu market estimates and forecasts, 2018 - 2030
  • FIG. 30 Adcetris market estimates and forecasts, 2018 - 2030
  • FIG. 31 Padcev market estimates and forecasts, 2018 - 2030
  • FIG. 32 Trodelvy market estimates and forecasts, 2018 - 2030
  • FIG. 33 Polivy market estimates and forecasts, 2018 - 2030
  • FIG. 34 Others market estimates and forecasts, 2018 - 2030
  • FIG. 35 Antibody-drug conjugates market: Target outlook and key takeaways
  • FIG. 36 Antibody-drug conjugates market: Target movement analysis
  • FIG. 37 HER2 market estimates and forecasts, 2018 - 2030
  • FIG. 38 CD22 market estimates and forecasts, 2018 - 2030
  • FIG. 39 CD30 market estimates and forecasts, 2018 - 2030
  • FIG. 40 Others market estimates and forecasts, 2018 - 2030
  • FIG. 41 Antibody-drug conjugates market: Technology outlook and key takeaways
  • FIG. 42 Antibody-drug conjugates market: Technology movement analysis
  • FIG. 43 Cleavable linker market estimates and forecasts, 2018 - 2030
  • FIG. 44 Non-cleavable linker market estimates and forecasts, 2018 - 2030
  • FIG. 45 Linkerless market estimates and forecasts, 2018 - 2030
  • FIG. 46 VC (valine-citrulline) market estimates and forecasts, 2018 - 2030
  • FIG. 47 Sulfo-SPDB market estimates and forecasts, 2018 - 2030
  • FIG. 48 VA (valine alanine) market estimates and forecasts, 2018 - 2030
  • FIG. 49 Hydrazone market estimates and forecasts, 2018 - 2030
  • FIG. 50 Others market estimates and forecasts, 2018 - 2030
  • FIG. 51 MMAE market estimates and forecasts, 2018 - 2030
  • FIG. 52 MMAF market estimates and forecasts, 2018 - 2030
  • FIG. 53 DM4 market estimates and forecasts, 2018 - 2030
  • FIG. 54 Camptothecin market estimates and forecasts, 2018 - 2030
  • FIG. 55 Others market estimates and forecasts, 2018 - 2030
  • FIG. 56 Antibody-drug conjugates market: Regional outlook and key takeaways
  • FIG. 57 Antibody-drug conjugates market: Regional movement analysis
  • FIG. 58 North America SWOT analysis
  • FIG. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 U.S. key country dynamics
  • FIG. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Canada key country dynamics
  • FIG. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Europe SWOT analysis
  • FIG. 65 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 UK key country dynamics
  • FIG. 67 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Germany key country dynamics
  • FIG. 69 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Italy key country dynamics
  • FIG. 71 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Spain key country dynamics
  • FIG. 73 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 Denmark key country dynamics
  • FIG. 75 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Sweden key country dynamics
  • FIG. 77 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 78 Norway key country dynamics
  • FIG. 79 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 80 France key country dynamics
  • FIG. 81 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 82 Asia Pacific SWOT analysis
  • FIG. 83 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 84 Japan key country dynamics
  • FIG. 85 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 86 China key country dynamics
  • FIG. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 88 India key country dynamics
  • FIG. 89 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 90 Australia key country dynamics
  • FIG. 91 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 92 South Korea key country dynamics
  • FIG. 93 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 94 Thailand key country dynamics
  • FIG. 95 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 96 Latin America SWOT analysis
  • FIG. 97 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 98 Brazil key country dynamics
  • FIG. 99 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 100 Mexico key country dynamics
  • FIG. 101 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 102 Argentina key country dynamics
  • FIG. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 104 Middle East & Africa SWOT analysis
  • FIG. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 106 South Africa key country dynamics
  • FIG. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 108 Saudi Arabia key country dynamics
  • FIG. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 110 UAE key country dynamics
  • FIG. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 112 Kuwait key country dynamics
  • FIG. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 114 Company market share analysis
  • FIG. 115 Company market position analysis (Revenue US$ mn)
  • FIG. 116 Company market position analysis (Profit Margin)
  • FIG. 117 Competitive dashboard analysis
  • FIG. 118 Regional Network Map